活動性特発性炎症性筋症患者におけるCABA-201の安全性と有効性を評価する非盲検試験
活動性特発性炎症性筋症患者における自己 CD19 特異的キメラ抗原受容体 T 細胞 (CABA-201) の安全性と有効性を評価する第 1/2 相非盲検試験
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Cabaletta Bio
- 電話番号:4444 267-759-3100
- メール:clinicaltrials@cabalettabio.com
研究場所
-
-
California
-
Orange、California、アメリカ、92868
- 募集
- University of California Irvine - Accepting Adult Patients
-
主任研究者:
- Tahseen Mozaffar, MD
-
コンタクト:
- Alpha Clinic
- 電話番号:949-824-3990
- メール:alphaclinic@uci.edu
-
San Francisco、California、アメリカ、94158
- 募集
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
コンタクト:
- Zilan Zheng
- 電話番号:415-353-1301
- メール:Zilan.Zheng@ucsf.edu
-
主任研究者:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora、Colorado、アメリカ、80046
- 募集
- Children's Hospital Colorado - Accepting Juvenile Patients
-
主任研究者:
- Dr. Kentaro Yomogida, MD
-
コンタクト:
- Callie Strini - Primary Clinical Research Coordinator
- 電話番号:720-777-9845
- メール:callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- Mayo Clinic Florida - Accepting Adult Patients
-
コンタクト:
- Gabrielle Pariseau
- 電話番号:904-953-5549
- メール:pariseau.gabrielle@mayo.edu
-
St. Petersburg、Florida、アメリカ、33701
- 募集
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
主任研究者:
- Natalie Booth, DO
-
コンタクト:
- Laura Escobar
- 電話番号:727-767-2946
- メール:llabarr2@jh.edu
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30032
- 募集
- Emory University - Accepting Adult Patients
-
コンタクト:
- John Varghese
- メール:john.varghese@emory.edu
-
主任研究者:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta、Georgia、アメリカ、30029
- 募集
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
主任研究者:
- Shanmuganathan Chandrakasan, MD
-
コンタクト:
- Judson Russell
- 電話番号:404-785-7263
- メール:Judson.russell@choa.org
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern Memorial Hospital - Accepting Adult Patients
-
主任研究者:
- Dr. George Georges, MD
-
コンタクト:
- Kaitlin King
- 電話番号:312-695-0990
- メール:autoimmunesct@nm.org
-
Chicago、Illinois、アメリカ、60637
- 募集
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
主任研究者:
- Dr. Iazsmin Ventura, MD
-
コンタクト:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- 電話番号:773-702-6619
- メール:iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
副調査官:
- Dr. Cuoghi Edens, MD, FAAP
-
コンタクト:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- メール:cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago、Illinois、アメリカ、60611
- 募集
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
コンタクト:
- Tyler Sorensen
- 電話番号:312-277-6828
- メール:tsorensen@luriechildrens.org
-
主任研究者:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- University of Kansas Medical Center - Accepting Adult Patients
-
コンタクト:
- Samantha Colgan
- 電話番号:913-945-9938
- メール:scolgan@kumc.edu
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- 募集
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
コンタクト:
- Julie Thompson
- 電話番号:301-480-3191
- メール:Julie.thompson@nih.gov
-
主任研究者:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- 募集
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
主任研究者:
- Susan Prockop, MD
-
コンタクト:
- Kyle McBrearty
- 電話番号:617-355-2780
- メール:kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48105
- 募集
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
コンタクト:
- Abigail Whalen
- 電話番号:734-615-4466
- メール:abigaiwh@med.umich.edu
-
主任研究者:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55902
- 募集
- Mayo Clinic - Accepting Adult Patients
-
コンタクト:
- Bridget Neja
- 電話番号:507-266-9150
- メール:neja.bridget@mayo.edu
-
-
New York
-
New York、New York、アメリカ、10021
- 募集
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
コンタクト:
- Janvi Bhatia
- 電話番号:212-774-2123
- メール:bhatiaj@hss.edu
-
主任研究者:
- David R. Fernandez, MD, PhD
-
New York、New York、アメリカ、10021
- 募集
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
主任研究者:
- Jae Park, MD
-
コンタクト:
- Atifah Osrat
- 電話番号:646-608-2091
- メール:osrata1@mskcc.org
-
The Bronx、New York、アメリカ、10467
- 募集
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
コンタクト:
- Emily Gillies
- 電話番号:718-696-2402
- メール:egillies@montefiore.org
-
主任研究者:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- 募集
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
主任研究者:
- Saira Sheikh, MD
-
コンタクト:
- Leah Luizza
- メール:leah.luizza@med.unc.edu
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
主任研究者:
- Kaveh Ardalan, MD, MS
-
コンタクト:
- Lynn Rodgers, MS
- 電話番号:919-668-2953
- メール:Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- 募集
- Oregon Health & Science University - Accepting Adult Patients
-
コンタクト:
- Katie Lewis
- 電話番号:503-908-9724
- メール:lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
コンタクト:
- CARTintake@chop.edu
- メール:CARTintake@chop.edu
-
主任研究者:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh、Pennsylvania、アメリカ、15261
- 募集
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
コンタクト:
- Carol Oriss
- メール:orissca@upmc.edu
-
主任研究者:
- Jeremy Tilstra, MD
-
Pittsburgh、Pennsylvania、アメリカ、15224
- 募集
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
コンタクト:
- Vibha Chauhan, PhD
- 電話番号:412-692-7924
- メール:Vibha.chauhan@chp.edu
-
主任研究者:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University Medical Center - Accepting Adult Patients
-
コンタクト:
- Tofi Soneye
- 電話番号:817-883-4730
- メール:tofi.soneye@vumc.org
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
主任研究者:
- Samuel John, MD
-
コンタクト:
- Dr. Samuel John
- メール:dtpteam@childrens.com
-
Houston、Texas、アメリカ、77030
- 募集
- Houston Methodist Hospital - Accepting Adult Patients
-
コンタクト:
- Amelia A. Nounes, MSN, RN, CCRP
- 電話番号:346-356-3639
- メール:aanounes@houstonmethodist.org
-
Houston、Texas、アメリカ、77030
- 募集
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
主任研究者:
- Huifang (Linda) Lu, MD
-
コンタクト:
- Christina Amos Briggs, BSN, RN
- 電話番号:713-563-5076
- メール:cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113
- 募集
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
コンタクト:
- Morgan Badgley - Research Coordinator
- 電話番号:801-662-4812
- メール:morgan.badgley@hsc.utah.edu
-
主任研究者:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- 募集
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
コンタクト:
- Dr. Susan Shenoi, MD, MS
- 電話番号:206-987-2193
- メール:susan.shenoi@SeattleChildrens.org
-
主任研究者:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- まだ募集していません
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
主任研究者:
- Sara Sabbagh, DO
-
コンタクト:
- Erin Hammelev - Research Coordinator
- 電話番号:414-337-7064
- メール:ehammele@mcw.edu
-
-
-
-
-
London、イギリス、WC1N 3BG
- 募集
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
コンタクト:
- Dr. Pedro Machado, FRCP, PhD
- 電話番号:020 3456 7890
- メール:uclh.car-ttrials@nhs.net
-
主任研究者:
- Dr. Pedro Machado, FRCP, PhD
-
London、イギリス、SE5 9RS
- 募集
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
コンタクト:
- Rheumatology Research Team
- 電話番号:0628 0207 848 0214
- メール:Kch-tr.CRDresearch@nhs.net
-
主任研究者:
- Patrick Gordon, PhD, FRCP, MBBS
-
London、イギリス、WC1N 3JH
- 募集
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
コンタクト:
- Professor Despina Eleftheriou
- 電話番号:020 7405 9200
- メール:Despina.Eleftheriou@gosh.nhs.uk
-
主任研究者:
- Professor Despina Eleftheriou
-
Manchester、イギリス、M13 9WL
- 募集
- Manchester Royal Infirmary - Accepting Adult Patients
-
コンタクト:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- 電話番号:01612765052
- メール:Eleni.Tholouli@mft.nhs.uk
-
主任研究者:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford、イギリス、M6 8HD
- 募集
- Salford Royal Hospital - Accepting Adult Patients
-
コンタクト:
- Michelle Beswick
- 電話番号:07759 136787
- メール:Rheumatology.Research@nca.nhs.uk
-
主任研究者:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
-
Roma、イタリア、00165
- 募集
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
コンタクト:
- Dr. Marco Becilli
- 電話番号:+39 0668592739
- メール:marco.becilli@opbg.net
-
主任研究者:
- Professor Franco Locatelli
-
-
-
-
-
Göttingen、ドイツ、37075
- まだ募集していません
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
コンタクト:
- Dr. Jana Zschüntzsch
- メール:j.zschuentzsch@med.uni-goettingen.de
-
主任研究者:
- Dr. Jana Zschüntzsch
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
他の名前:
|
|
実験的:CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
他の名前:
|
|
実験的:CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
時間枠:Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
時間枠:Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
時間枠:Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
時間枠:Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
時間枠:Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
時間枠:Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
時間枠:Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
時間枠:Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
時間枠:Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
時間枠:Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
時間枠:Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
時間枠:Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
時間枠:Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
時間枠:Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
時間枠:Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
協力者と研究者
捜査官
捜査官
- スタディチェア:Medical Director、Cabaletta Bio
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CAB-201-002
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。